Pegevongitide

N/A

Report date: 2026/04/18 20:00:19
NME

Base Information

Drug NamePegevongitide
Drug Alias NameAV-001
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionTEK receptor tyrosine kinase agonists
TargetsTEK receptor tyrosine kinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Brain InjuriesRespiratory Distress Syndrome, Adult +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSunnybrook Health Sciences CentreVasomune Therapeutics IncAnges Inc
China Registration ClassN/A

Develop Information

Active CompaniesLondon Health Sciences Centre Research InstituteAnges IncVasomune Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsBrain InjuriesRespiratory Distress Syndrome, AdultPneumonia, Viral +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A